Otsuka Holdings Co., Ltd. (OTSKF)
| Market Cap | 33.90B |
| Revenue (ttm) | 15.75B |
| Net Income (ttm) | 2.32B |
| Shares Out | n/a |
| EPS (ttm) | 4.37 |
| PE Ratio | 14.64 |
| Forward PE | n/a |
| Dividend | 0.93 (1.39%) |
| Ex-Dividend Date | Dec 29, 2025 |
| Volume | n/a |
| Average Volume | 1,102 |
| Open | 67.11 |
| Previous Close | 67.11 |
| Day's Range | 67.11 - 67.11 |
| 52-Week Range | 44.40 - 70.19 |
| Beta | -0.13 |
| RSI | 65.12 |
| Earnings Date | Feb 13, 2026 |
About Otsuka Holdings
Otsuka Holdings Co., Ltd. engages in the pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide. It develops pharmaceutical products in the fields of psychiatry, neurology, oncology, cardiovascular and renal system, autoimmune space digestive system, ophthalmology, and diagnostics, as well as intravenous solutions and medical devices. It also provides clinical testing, medical equipment and tools, food products, cosmetics, functional food products, chemical products, soft drinks, beverages, analytical and measurement... [Read more]
Financial Performance
In 2025, Otsuka Holdings's revenue was 2.47 trillion, an increase of 5.97% compared to the previous year's 2.33 trillion. Earnings were 363.15 billion, an increase of 5.84%.
Financial numbers in JPY Financial StatementsNews
Otsuka Holdings Co., Ltd. 2025 Q4 - Results - Earnings Call Presentation
Otsuka Holdings Co., Ltd. (OTSKY) Q4 2025 Earnings Call Prepared Remarks Transcript
Otsuka Holdings Co., Ltd. (OTSKY) Q4 2025 Earnings Call Prepared Remarks Transcript
Full Year 2025 Otsuka Holdings Co Ltd Earnings Presentation Transcript
Full Year 2025 Otsuka Holdings Co Ltd Earnings Presentation Transcript
Otsuka Holdings FY25 Profit Rises, Sees Weak Profit In H1, FY26
(RTTNews) - Otsuka Holdings Co. (OTSKF, 4578.T) Friday reported higher profit in fiscal 2025 with increased revenues. Further, the Japanese Pharmaceutical firm issued its first half and fiscal 2026 ou...
US FDA approves Otsuka's kidney disease drug
The U.S. Food and Drug Administration has approved Otsuka's injectable drug to treat patients with a potentially life-threatening kidney disease, the health regulator's website showed on Tuesday.
Shares of Asian drugmakers drop after Trump threatens tariffs
Shares of Asian drugmakers mostly fell on Friday after U.S. President Donald Trump threatened 100% tariffs on imports of branded pharmaceuticals from October 1, unless their producers had already brok...
Otsuka Corporation (OSUKF) Q1 FY2025 Earnings Call Transcript
Otsuka Corporation (OTCPK:OSUKF) Q1 FY2025 Earnings Conference Call August 1, 2025 2:30 AM ET Company Participants Yuji Otsuka - CEO, President, Chairman & MM Division Chief Yuji Otsuka I am Otsuka of...
Otsuka Holdings Co., Ltd. (OTSKY) Q2 FY2024 Earnings Call Transcript
Otsuka Holdings Co., Ltd. (OTCPK:OTSKY) Q2 FY2024 Earnings Call July 31, 2025 ET Company Participants Tatsuo Higuchi - Advisor, Chairman Emeritus & Senior Executive Director Tomohiro Emura - Executive...